Abbott Laboratories ( ABT) snapped six consecutive sessions of losses as the stock gained 1.21% to close at $103.18 on Monday ...
Abbott Laboratories stock is emerging as a key way to play a potential rebound in healthcare, with analysts arguing that fundamentals are finally set to matter again after a choppy stretch for the ...
On September 17, 2026, Abbott Laboratories’ board of directors declared a quarterly common dividend of USD 0.63 per share, ...
Analysts keep raising their price targets on this 54-year dividend raiser. Here are the reasons behind the newfound confidence.
Valued at a market cap of $194.6 billion, Abbott Laboratories (ABT) is a global healthcare company that discovers, develops, manufactures, and sells a wide range of healthcare products across various ...
ABT's earnings beat and higher profit outlook strengthen its case, but can growth in devices and diagnostics overcome valuation and acquisition concerns?
Worried about a pullback? This Dividend King pairs a 54-year streak with catalysts that could provide income even if the ...
Abbott Laboratories (ABT) shares are experiencing a massive technical shift in Thursday afternoon trading, surging over 10% on the heels of better-than-expected second-quarter 2026 earnings and a ...
At the close on September 16, 2026, Abbott Laboratories stock slipped modestly on the NYSE, underperforming the S&P 500 while ...
FDA approval for TactiFlex Duo expands ABT's AFib ablation portfolio with dual PFA and RF energy options, supporting broader U.S. adoption.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results